Skip to main content

Table 4 Univariate analysis of prognostic factors of SRH in PPFE

From: Impact of sleep-related hypoventilation in patients with pleuroparenchymal fibroelastosis

Ā 

HR [95% CI]

p-value

Age

1.02 [.98ā€“1.06]

.37

Smoking history

2.19 [.81ā€“5.92]

.12

BMI

.77 [.64ā€“.94]

ā€‰<ā€‰.01

Gender male

1.27 [.43ā€“3.74]

.66

PaCO2

1.01 [.96ā€“1.05]

.76

HCO3āˆ’

1.08 [.95ā€“1.24]

.25

PtCO2 mean

.98 [.94ā€“1.03]

.45

PtCO2 max

.99 [.96ā€“1.03]

.69

%FEV1

.96 [.25ā€“3.68]

.95

FEV1/FVC

1.01 [.96ā€“1.07]

.66

%VC

1.00 [.97ā€“1.04]

.83

%FVC

.99 [.96ā€“1.03]

.73

%TLC

1.02 [.98ā€“1.06]

.35

%RV

1.01 [.99ā€“1.04]

.31

%RV/TLC

1.00 [.98ā€“1.02]

.77

%DLCO

1.00 [.98ā€“1.03]

.88

%DLCO/VA

.99 [.97ā€“1.02]

.63

KL-6

1.00 [.99ā€“1.01]

.94

GAP score stage

1.07 [.54ā€“2.13]

.85

Flat chest index

.42 [.01ā€“50.00]

.72

HOTā€‰+ā€‰NPPV

.25 [.06ā€“1.12]

.07

  1. The data are presented as hazard ratio [95% confidence interval]
  2. HR hazard ratio, CI confidence interval, SRH sleep-related hypoventilation, PPFE pleuroparenchymal fibroelastosis, BMI body mass index, PaCO2 arterial carbon dioxide partial pressure in awaking, PtCO2 transcutaneous carbon dioxide monitoring during sleep, HCO3āˆ’ hydrogen carbonate in awaking arterial blood gas analysis, %FEV1%forced expiratory volume in one second, %FVC %forced vital capacity, FEV1/FVC forced expiratory volume in one second/forced vital capacity, %VC %vital capacity; %TLC %total lung capacity, %RV %residual volume, %DLCO %diffusing capacity for carbon monoxide, %DLCO/VA %diffusing capacity for carbon monoxide, KL-6 Krebs von den lungen-6, GAP gender-age-physiology, HOTā€‰+ā€‰NPPV introducing home oxygen therapy (HOT) in daytime plus non-invasive positive pressure ventilation (NPPV)